News On Projects
Products & Services
Projects Database
Tenders Database
E - Newsletter
EPXonline.com
Project Financing
Contracts & Awards
Energy
Electricity
Mining
Oil & Gas
Infrastructure
Airport
Port
Railway
Road
Freezone
Construction
Manufacturing
Cement
Engineering
Automobile
Plastic
Metal
Textile
Paper & Packaging
Leather
Sugar
Edible Oil
Electrical & Electro
Processing
Chemical
Drugs & Pharma
Fertiliser
I-C-T
Communication
IT
Telecom
Water
Pump Station
Water Treatment
Water Supply
Hospitality
Hotel
Restaurant
Resort
Entertainment
Sports
Multiplex
Theme Park
Food & Beverages
Hospital
Service
Social
Science
Irrigation
Government
Policy
Economic Indicators
Company News
Commerce
Miscellaneous
News Uploaded On : Thursday, May 19, 2016 1:46:00 PM IND Back  |  Latest Projects  |  Latest Tenders
 
 E-mail this to a friend        Printable version       Story Viewed 2329 Times
China’s Fosun bids to buy India’s Gland Pharma.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd, the Hong Kong-listed company controlled by billionaire Guo Guangchang, said it had submitted a non-binding proposal to acquire a 96% stake in India’s Gland Pharma Ltd.

Private equity firm KKR and Co. owns a significant minority stake in Gland Pharma.

On 9 May, Fosun Industrial Co. Ltd, a unit of the Chinese drug maker, made a non-binding proposal to existing shareholders of Gland Pharma, the company said in a statement to the Hong Kong stock exchange on Monday.

Fosun’s bid for a controlling stake in Gland Pharma is a rare instance of a Chinese drug maker seeking to buy an Indian company. Foreign investments from China have long been viewed with suspicion in India.

“As at the date of this announcement, the non-binding proposal is still in a bidding process on a non-exclusive basis, which shall be confirmed by the relevant parties pending the selection and acceptance by the existing shareholders of Gland,” the statement said.

In the event that the non-binding proposal made by Fosun Industrial is successful, “it will enhance and improve the Group’s drug manufacture and research and development capacity and the degree of internationalization,” it added.

US pharma major Baxter International Inc. has emerged the front-runner to buy Gland Pharma for over $1 billion, The Economic Times reported.

In 2013, KKR spent around $200 million to buy an undisclosed stake in Gland from Evolvence India Life Sciences Fund.

Advent International, Baxter and Torrent Pharmaceuticals Ltd are among contenders for Gland Pharma, Reuters reported last month.

An Advent spokesperson declined to comment. Gland Pharma, Baxter and Torrent Pharma did not respond to e-mails seeking comment. A KKR spokesperson didn’t respond to an e-mail.

Established in 1978 and based in Hyderabad, Gland Pharma develops and manufactures generic injectables, primarily for the US market. It also sells its products in India and other semi-regulated markets. Its manufacturing facilities are approved by the US and UK drug regulators.

Livemint

Post your comments:

Your name: *
E-Mail Id:
E-mail ID will not be published
Comment: *
Maximum 500 Characters
    
Related Stories
Alembic Pharma forms JV with Orbicular for derma products.
Rusan Pharma aims to double turnover to Rs 600 cr by 2018
Indoco Remedies shares soar 19% on USFDA nod for Goa plant.
GSK Pharma plans Rs. 500-cr expansion of its Nashik unit.
Mankind Pharma to invest Rs. 150 crore in Paonta Sahib plant.
Green panel okays Aurobindo Pharma's Telangana unit expansion.
GSK begins work on new factory to make tablets and capsules.
IICT promises to assist pharma industry in AP.
IDPL modernises tablet making unit at Gurgaon plant.
Aurobindo Pharma to build three formulation plants in Andhra Pradesh, Telangana.
RELATED PROJECTS & TENDERS
ADVERTISEMENT
MOST POPULAR STORIES NOW
For all enquiries please contact
Tel: 022 - 25961254, 25960909
Mobile: 9821464666/09751178830
Mail: marketing@newsonprojects.com

OUR OTHER PRODUCTS & SERVICES:    Projects Database   |   Project e-Newsletter   |   Tenders Database   |   Commissioned Power Plants   |   Company Index
About Us   |   Contact Us   |   Terms of Use   |   Advertise with Us   |   Privacy Policy   |   Disclaimer   |   Feedback